Bristol Myers greenlights neurodegenerative medicine from Evotec pact for $20M
Evotec is headed to the bank with a cool $20 million after Bristol Myers Squibb opted in on a neurodegenerative medicine called EVT8683.
Evotec is headed to the bank with a cool $20 million after Bristol Myers Squibb opted in on a neurodegenerative medicine called EVT8683.
Disc Medicine has raised $90 million in a series B round as it looks to push on with its pipeline of early- to midstage blood disorder assets.
Investors are taking the departure of Avidity Biosciences’ chief medical officer badly. After learning Jae Kim had left for personal reasons, just days after giving his notice and on the day Avidity posted details of its first study to ClinicalTrials.gov, investors drove the stock down 19%.
Sometimes, it’s not a real human on the other end of the line. Like everything else these days, IQVIA is expanding its virtual work by leveraging artificial-intelligence-powered agents.
Brickell Biotech is picking up an inhibitor platform with multiple assets that aim to restore immune balance in an exclusive rights deal that could balloon over $300 million.
Astellas’ $3 billion bet on Audentes Therapeutics has hit yet another setback. Months after getting a clinical hold lifted, Astellas has voluntarily paused a gene therapy clinical trial after a patient suffered liver problems at the lower, supposedly safer dose.
More money is flowing into the natural killer (NK) cell therapy space. HebeCell is the latest biotech to grow its bank balance, raising $53 million in a round led by a Chinese drug developer to advance its off-the-shelf CAR-NK prospects.
Asher Biotherapeutics is not the only biotech looking to improve upon the first generation of cytokine immunotherapies hampered by limited efficacy, tolerability and safety issues, but investors have taken note of the selectivity of the startup’s cis-targeting platform and are confident enough to dole out $108 million.
Cancer trial matchmaker Massive Bio is teaming up with two organizations to boost clinical studies and research participation for prostate cancer.
It’s no secret that drug development is a tough business, with the majority of efforts never reaching approval.